MedTrace Logo

In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?

NCT02937155 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-11-22

No results posted yet for this study

Summary

This study will look at cervical tissue samples in women with abnormal cervical cells to see if the frequency of the HPV 16/18 subtypes has changed in female populations today, after the introduction of the HPV vaccine. It will compare women who have been exposed to the HPV vaccine with those who have not.

Conditions

  • HSIL, High-Grade Squamous Intraepithelial Lesions
  • Adenocarcinoma in Situ
  • Early Cervical Cancer

Sponsors & Collaborators

  • Merck Canada Inc.

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Allan Covens, MD · Sunnybrook Health Sciences Centre

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-06-30
Completion
2024-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02937155 on ClinicalTrials.gov